Teva's US-listed shares up as FDA approves Humira biosimilar

Alvotech SA

26/02/2024 11:14

** U.S.-listed shares  TEVA.N  of Teva Pharmaceutical rise
5.5% to $13.60 premarket
    ** Late on Sunday, company and partner Alvotech  ALVO.O 
said U.S. Food and Drug Administration approved Simlandi
injection, a biosimilar of Abbvie's  ABBV.N  blockbuster
rheumatoid arthritis drug Humira
    ** ALVO shares up ~13% at $18.04 premarket on Monday
    ** Teva, along with partner ALVO, expects to launch Simlandi
in the U.S. imminently
    ** As of last close, Teva's U.S.-listed shares up ~24%,
while ALVO up ~40% this year

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788))